The Piracetam-nootropics (pyrrolidone derivatives) have been exhaustively researched for more than three decades. Experimental and clinical work first focused on their so-called nootropic effects; later came the possibilities for neuroprotection after stroke and use as antiepileptic agents. The concept and definition of a “nootropic drug” was first proposed in 1972 by C.E. Guirgea, the principal Piracetam researcher for UCB Pharmaceutical Company of Belgium that launched Piracetam. He coined the term”nootropic” from the italic words “noos” (mind) and “tropein” (to turn toward), to mean enhancement of learning and memory.
Click the link above to download the full article in a new browser window or new tab.